ANGO

AngioDynamics, Inc. 10-K Summary (Fiscal Year Ended May 29, 2004)

Business Context and Reporting Period

Company: AngioDynamics, Inc.
Reporting Period: Fiscal year ended May 29, 2004 (52 weeks).
Business Overview: AngioDynamics designs, develops, manufactures, and markets innovative medical devices for minimally invasive, image-guided procedures to treat peripheral vascular disease (PVD) and other non-coronary diseases. Key product lines include angiographic catheters, hemodialysis catheters, and the VenaCure endovascular laser system.
Corporate Status: Historically a wholly-owned subsidiary of E-Z-EM, Inc., the company completed its Initial Public Offering (IPO) on May 27, 2004. As of the filing date, E-Z-EM retained approximately 80.4% ownership, with a planned distribution of shares to E-Z-EM stockholders scheduled for October 30, 2004.

Key Financial Metrics

Note: Total debt decreased significantly due to the capitalization of $13.1 million in parent company debt and the repayment of $3.0 million in notes payable using IPO proceeds.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 27.9% to $49.1 million, driven by new product introductions (specifically the Dura-Flow hemodialysis catheter and VenaCure laser system) and expansion of the domestic sales force.
• Profitability: Net earnings more than doubled to $3.1 million. Operating profit margin improved to 10.4% from 8.5% due to increased sales volume, favorable product mix, and manufacturing efficiencies.
• Capital Structure: The company transitioned from being a private subsidiary to a public entity. The IPO generated approximately $21.5 million in net proceeds (received post-fiscal year-end). Long-term debt to the parent company was largely converted to equity.
• Product Mix: VenaCure products grew from 5.5% of sales in 2003 to 11.5% in 2004. Hemodialysis catheters remained the second-largest category at 27.3%.

Guidance, Outlook, Risks, and Contingencies

• Outlook: Management expects R&D expenditures to increase to approximately 8% of net sales. The company plans to manufacture more products in-house to reduce costs and improve margins. No cash dividends are anticipated in the foreseeable future.
• Key Risks:
  • Competition: Intense competition from larger firms (e.g., Boston Scientific, Cook) with greater resources.
  • Supplier Dependence: Reliance on single-source suppliers for critical components, including Medcomp (hemodialysis catheters) and biolitec (VenaCure lasers).
  • Reimbursement: Dependence on third-party payors (Medicare, private insurers) for coverage of procedures using AngioDynamics devices.
  • Intellectual Property: Risk of patent infringement litigation.
• Legal Contingencies:
  • Diomed Litigation: Diomed, Inc. filed a patent infringement suit in January 2004 regarding the VenaCure products. The company believes it does not infringe and is being defended by biolitec.
  • Product Liability: A lawsuit (Duhon et al.) alleges a defective catheter caused a patient's death. The supplier, Medcomp, has accepted the defense and indemnification obligation.

Investor Verification Checklist

• IPO Proceeds Utilization: Verify the deployment of the ~$21.5 million in net IPO proceeds received in June 2004, specifically regarding the repayment of the $3.0 million note to E-Z-EM.
• Spin-off Timeline: Confirm the status of the planned distribution of AngioDynamics shares to E-Z-EM stockholders, scheduled for October 30, 2004.
• Supplier Agreements: Review the terms and expiration dates of exclusive supply agreements with Medcomp (expires March 2007) and biolitec (expires March 2007).
• Legal Exposure: Monitor the progress of the Diomed patent infringement lawsuit, as VenaCure products represent 11.5% of total sales.
• Debt Covenants: Review compliance with financial covenants related to the industrial revenue bonds used for facility expansion.